welcomes you to the new, improved website!The Amsterdam Investigator-initiated Absorb Strategy All-comers Trial report safety concerns identified in early results for the bioresorbable scaffold drug eluting stent. The scaffold group experienced significantly higher rates of device thrombosis than the stent group (3.5% vs 0.9%; p
You are here:
Bioresorbable Scaffolds versus Metallic Stents in Routine PCI
Submitted by: Aristotle Protopapas
Source: The New England Journal of Medicine
Keywords:
Author(s): Joanna J. Wykrzykowska, Robin P. Kraak, Sjoerd H. Hofma, Rene J. van der Schaaf, E. Karin Arkenbout, Alexander J. IJsselmuiden, Joëlle Elias, Ivo M. van Dongen, Ruben Y.G. Tijssen, Karel T. Koch, Jan Baan, Jr., M. Marije Vis, Robbert J. de Winter, Jan J. Piek, Jan G.P. Tijssen, Jose P.S. Henriques
